Business Description
Verastem Inc
NAICS : 325412
SIC : 2834
ISIN : US92337C1045
Total Employee Number:
102Description
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.62 | |||||
Equity-to-Asset | 0.24 | |||||
Debt-to-Equity | 1.69 | |||||
Debt-to-EBITDA | -0.42 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -7.74 | |||||
Beneish M-Score | 32.75 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 40.4 | |||||
3-Year EBITDA Growth Rate | 12.3 | |||||
3-Year EPS without NRI Growth Rate | 17.2 | |||||
3-Year FCF Growth Rate | 18.7 | |||||
3-Year Book Growth Rate | -36.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 37.63 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 100.48 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 80.2 | |||||
9-Day RSI | 74.49 | |||||
14-Day RSI | 71.31 | |||||
3-1 Month Momentum % | 51.54 | |||||
6-1 Month Momentum % | 1.37 | |||||
12-1 Month Momentum % | -38.68 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.25 | |||||
Quick Ratio | 2.22 | |||||
Cash Ratio | 1.75 | |||||
Days Inventory | 57.93 | |||||
Days Sales Outstanding | 49.86 | |||||
Days Payable | 354.39 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -66.9 | |||||
Shareholder Yield % | -16.43 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 86.35 | |||||
Operating Margin % | -182.57 | |||||
Net Margin % | -231.59 | |||||
EBITDA Margin % | -227.66 | |||||
FCF Margin % | -184.96 | |||||
OCF Margin % | -184.96 | |||||
ROE % | -483.79 | |||||
ROA % | -96.17 | |||||
ROIC % | -421.81 | |||||
3-Year ROIIC % | -304.44 | |||||
ROC (Joel Greenblatt) % | -13110.43 | |||||
ROCE % | -137.91 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 8.62 | |||||
PB Ratio | 14.87 | |||||
Price-to-Tangible-Book | 21.79 | |||||
EV-to-EBIT | -3.45 | |||||
EV-to-Forward-EBIT | -4.59 | |||||
EV-to-EBITDA | -3.47 | |||||
EV-to-Revenue | 7.9 | |||||
EV-to-Forward-Revenue | 4.03 | |||||
EV-to-FCF | -4.26 | |||||
Price-to-GF-Value | 0.15 | |||||
| Price-to-Net-Current-Asset-Value | 36.71 | |||||
Earnings Yield (Greenblatt) % | -28.99 | |||||
FCF Yield % | -21.81 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Verastem Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 75.491 | ||
| EPS (TTM) (€) | -2.1 | ||
| Beta | 1.3774 | ||
| 3-Year Sharpe Ratio | 0.35 | ||
| 3-Year Sortino Ratio | 0.58 | ||
| Volatility % | 76.17 | ||
| 14-Day RSI | 71.31 | ||
| 14-Day ATR (€) | 0.353805 | ||
| 20-Day SMA (€) | 6.179 | ||
| 12-1 Month Momentum % | -38.68 | ||
| 52-Week Range (€) | 2.925 - 9.4 | ||
| Shares Outstanding (Mil) | 90.56 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Verastem Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Verastem Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-03-04 16:30 | In 179 days | ||
| Annual report for 2026 | 2027-03-04 | In 178 days | ||
| Fourth quarter earnings results for 2026 | 2027-03-04 | In 178 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-04 08:00 | In 59 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 58 days | ||
| H.C. Wainwright Annual Global Investment Conference | 2026-09-14 12:00 | In 8 days | ||
| Cantor Global Healthcare Conference | 2026-09-10 08:35 | In 4 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 16:30 | 5.03 (+1.45%) | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 5.03 (+1.45%) | ||
| Verastem Oncology VS-7375 TARGET-D Conference Call | 2026-06-23 16:30 | 3.70 (+4.91%) |
Show
Entries
Verastem Inc Frequently Asked Questions
What is Verastem Inc(STU:2VS)'s stock price today?
The current price of STU:2VS is €6.97. The 52 week high of STU:2VS is €9.40 and 52 week low is €2.93.
When is next earnings date of Verastem Inc(STU:2VS)?
The next earnings date of Verastem Inc(STU:2VS) is 2026-11-04 Est..
Does Verastem Inc(STU:2VS) pay dividends? If so, how much?
Verastem Inc(STU:2VS) does not pay dividend.
Press Release
Articles on Verastem Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers